AUTHORS
Lilian Antunes Heck, PhD, Brooke Sadler, PhD2, Thomas J. Girard, PhD3, Pamela Christopherson, N/A4, Veronica Flood, MD5, Nathan Stitziel, MD, PhD6, David Lillicrap Jr, MD7, James O'Donnell I, DSc, PhD, MB8, Karl Desch, MD9, Jorge Di Paola, MD10, New Zimmerman Program Investigators11
AFFILIATIONS
1 Washington University School of Medicine, Saint Louis, Missouri, United States
2 Washington University School of Medicine, Saint Louis, Missouri, United States
3 Washington University School of Medicine, Saint Louis, Missouri, United States
4 Versiti Blood Research Institute, Milwaukee, Wisconsin, United States
5 Versiti Blood Research Institute, Milwaukee, Wisconsin, United States
6 Washington University School of Medicine, Saint Louis, Missouri, United States
7 Queen's University, Kingston, Ontario, Canada
8 Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland
9 University of Michigan, Ann Arbor, Michigan, United States
10 Washington University School of Medicine, Saint Louis, Missouri, United States
11 Washington University School of Medicine, Saint Louis, Missouri, United States
ABSTRACT
Background: Approximately 35–50% of patients with Type 1 von Willebrand disease (VWD) lack pathogenic variants in VWF, leaving the biological basis of low VWF levels unresolved. We hypothesized that circulating plasma proteins capture biological pathways underlying genetically unexplained low VWF and may also serve as modifiers of the bleeding phenotype. Aims: (1) To identify circulating plasma proteins and biological pathways associated with low VWF levels in patients without pathogenic VWF variants. (2) To determine whether these proteins and biological pathways explain clinical bleeding severity.
Methods: Plasma proteomic profiling was performed using the SomaScan 11K aptamer platform in two independent cohorts (N=297): the New Zimmerman Program (135 Type 1 VWD [VWF 30–50 IU/dL] and 77 controls with normal VWF [ >50 IU/dL]) and the Genes and Blood Clotting study (43 low-tail VWF [<55 IU/dL] and 42 high-tail VWF [>200 IU/dL] healthy participants). Proteome-wide associations with VWF levels were evaluated using empirical Bayes linear regression (limma), before and after adjustment for age, sex, and ABO blood group. Only proteins significant after multiple-testing correction (FDR<5%) in both models were retained. Additive and interaction regression models were used to evaluate associations with bleeding phenotypes.
Results: Proteome-wide analysis identified a reproducible plasma proteomic signature comprising 33 proteins (39 aptamers) associated with low VWF levels across both cohorts. Thirty-two of 33 proteins showed concurrent decreases with lower VWF levels, reflecting a coordinated biological program rather than isolated protein changes. As expected, VWF and F8 were among the strongest associations, validating the analytical approach and proteomic platform, while EP300, DHFR, and CLU emerged as candidate biological modifiers of genetically unexplained low VWF, representing individual candidate proteins for future mechanistic investigation. Multiple independent aptamers targeting FN1, FBLN5, and NID2 showed concordant associations, providing additional evidence of reproducibility. Unsupervised hierarchical clustering separated samples primarily according to VWF status despite using protein expression alone, demonstrating a robust and reproducible proteomic signature across two independent cohorts. Pathway enrichment and protein interaction analyses independently converged on two highly interconnected biological programs, defining systems-level proteomic remodeling involving an Endothelial/Extracellular Matrix network (including VWF, FN1, FBLN2, FBLN5, NID1, NID2, LTBP4, MFAP4 and QSOX1) and a Platelet/Hemostasis network (including VWF, FN1, F8, F5, QSOX1, and GP1BB), with VWF and FN1 acting as major network hubs that characterize the low VWF state. Despite evaluating eight complementary regression models, no circulating proteins demonstrated reproducible associations with bleeding phenotype after multiple-testing correction.
Conclusions: Patients with low VWF lacking pathogenic variants in the VWF gene exhibit a robust plasma proteomic signature involving coordinated endothelial extracellular matrix remodeling and hemostatic programs. Despite this system-level proteomic signature, no reproducible circulating protein associations with bleeding severity were identified, highlighting the biological complexity of bleeding and limitations of current phenotyping. Beyond identifying individual candidates, including EP300 (a regulator of endothelial transcription), DHFR (a key metabolic enzyme linked to vascular function), and CLU (an endothelial chaperone involved in VWF multimer stabilization), our proteomic analysis reveals a synchronized, multi-protein remodeling program in low VWF states, providing mechanistic candidates for future functional and genomic studies to help resolve the biological basis of genetically unexplained Type 1 VWD.
DISCLOSURES
Lilian Antunes Heck, PhD: No relevant conflicts of interest to declare.